Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
24.43
+0.50 (2.09%)
At close: May 18, 2026, 4:00 PM EDT
24.54
+0.11 (0.45%)
Pre-market: May 19, 2026, 4:06 AM EDT
Zymeworks Revenue
Zymeworks had revenue of $2.41M in the quarter ending March 31, 2026, a decrease of -91.12%. This brings the company's revenue in the last twelve months to $81.26M, down -12.98% year-over-year. In the year 2025, Zymeworks had annual revenue of $105.97M with 38.87% growth.
Revenue (ttm)
$81.26M
Revenue Growth
-12.98%
P/S Ratio
21.95
Revenue / Employee
$334,416
Employees
243
Market Cap
1.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 105.97M | 29.66M | 38.87% |
| Dec 31, 2024 | 76.30M | 292.00K | 0.38% |
| Dec 31, 2023 | 76.01M | -336.47M | -81.57% |
| Dec 31, 2022 | 412.48M | 385.80M | 1,446.03% |
| Dec 31, 2021 | 26.68M | -12.27M | -31.50% |
| Dec 31, 2020 | 38.95M | 9.41M | 31.84% |
| Dec 31, 2019 | 29.54M | -23.48M | -44.28% |
| Dec 31, 2018 | 53.02M | 1.26M | 2.43% |
| Dec 31, 2017 | 51.76M | 40.75M | 370.18% |
| Dec 31, 2016 | 11.01M | 1.35M | 13.96% |
| Dec 31, 2015 | 9.66M | 7.99M | 478.44% |
| Dec 31, 2014 | 1.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Harmony Biosciences Holdings | 899.11M |
| Vericel | 292.09M |
| Syndax Pharmaceuticals | 217.17M |
| Viridian Therapeutics | 70.92M |
| Agios Pharmaceuticals | 66.05M |
| uniQure | 18.09M |
| Taysha Gene Therapies | 7.47M |
ZYME News
- 4 days ago - Zymeworks authorizes share repurchase program of up to $125M - TheFly
- 4 days ago - Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock - GlobeNewsWire
- 6 days ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Zymeworks reports Q1 EPS (59c), consensus (10c) - TheFly
- 11 days ago - Zymeworks Earnings Call Transcript: Q1 2026 - Transcripts
- 11 days ago - Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 27 days ago - Zymeworks reports results from dose-escalation part of Phase 1 study for ZW191 - TheFly
- 27 days ago - Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 - GlobeNewsWire